Core Viewpoint - The stock of Zai Lab Limited (02509) rose over 8% following the announcement of clinical trial approval for its self-developed long-acting dual antibody QX027N, aimed at treating asthma and atopic dermatitis [1] Group 1: Clinical Developments - Zai Lab's long-acting dual antibody QX027N injection received implied clinical trial approval from the National Medical Products Administration, marking a significant step into clinical stages for the company's innovative dual antibody matrix in autoimmune and allergic diseases [1] - The company also announced a global exclusive collaboration and licensing agreement with Roche for its self-developed long-acting autoimmune dual antibody QX031N, granting Roche rights for research, development, registration, production, and commercialization [1] Group 2: Financial Aspects - Under the agreement with Roche, Zai Lab will receive an upfront payment of $75 million, with potential milestone payments of up to $995 million, along with tiered royalties on future product sales [1]
港股异动 | 荃信生物-B(02509)早盘涨超8% QX027N获得两项临床试验默示许可 拟用于治疗哮喘及特应性皮炎